News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ischemix Enrolls First Patient In Phase 2a Trial To Prevent Contrast-Induced Acute Kidney Injury


6/26/2014 7:32:30 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MAYNARD, Mass.--(BUSINESS WIRE)--Ischemix, Inc., a pharmaceutical company developing a portfolio of cytoprotective compounds to address serious diseases, is pleased to announce that it has successfully enrolled the first patient in a Phase 2a trial of its lead compound to prevent contrast-induced acute kidney injury (“CI-AKI”) in acute coronary syndrome patients undergoing coronary angiography (the “CARIN” trial). The Company’s lead compound, CMX-2043, is a chemically-modified, naturally-occurring molecule with an excellent safety profile that has demonstrated efficacy in a prior human clinical trial.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
Ischemix
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES